Microfluidic isolation and release of live disseminated breast tumor cells in bone marrow
PLOS ONE · 12.03.2025 · 20 (3) · e0319392
DOI: 10.1371/journal.pone.0319392 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 12.03.2025. Verfasst von Minh-Chau N Le und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical and Aerospace Engineering, Interdisciplinary Microsystems Group, Gainesville, Florida, United States of America. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Breast Neoplasms, Cell Separation, Bone Marrow. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Science Foundation, National Institutes of Health.
Abstract (Originalsprache)
Breast cancer represents a significant therapeutic challenge due to its aggressive nature and resistance to treatment. A major cause of treatment failure in breast cancer is the presence of rare, low-proliferative disseminated tumor cells (DTCs) in distant organs including the bone marrow. This study introduced a microfluidic-based approach to improve the immunodetection and isolation of these rare DTCs for downstream analysis, with an emphasis on optimizing immunocapture, release, and enrichment methods of live DTCs as compared to the standard approach for blood-borne circulating tumor cells (CTCs). EGFR (epidermal growth factor receptor) and EpCAM (epithelial cell adhesion molecule), two key cell surface markers in breast cancer, were validated as efficient cell capture targets for DTCs within microfluidic chambers. Furthermore, we demonstrated that a combination of 0.25% trypsin and impulse was the most effective for releasing captured cells, maintaining high viability, and preserving essential cellular characteristics. Using a metastatic mouse breast cancer model, we achieved a 47.9-fold enrichment of live DTCs. Analysis of blood and bone marrow samples obtained from a breast cancer patient with minimal residual disease at two timepoints revealed a reduction in CTCs and an increase in DTCs following adjuvant chemotherapy. This observation suggested a potential dynamic interplay between CTCs and DTCs in response to therapy. Our results underscore the potential of the microfluidic approach in enhancing DTC detection and shed light on the importance of monitoring both CTCs and DTCs in breast cancer prognosis and treatment response assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Mechanical and Aerospace Engineering, Interdisciplinary Microsystems Group, Gainesville, Florida, United States of America.
- Division of Neuro-Oncology, USC Keck Brain Tumor Center, University of Southern California Keck School of Medicine, Los Angeles, California, United States of America.
- J. Crayton Pruitt Family Department of Biomedical Engineering, GainesvilleFlorida, United States of America.
ORCID-Profile: Minh-Chau N Le, David D Tran
Förderung
- NCI NIH HHS
- National Science Foundation
- National Institutes of Health
- National Science Foundation Graduate Research Fellowship Program
- University of Florida
Zitieren
APA
Le, M. N., Chen, D., Smith, K. A., Tran, D. D., & Fan, Z. H. (2025). Microfluidic isolation and release of live disseminated breast tumor cells in bone marrow. PLOS ONE, 20(3), e0319392. https://doi.org/10.1371/journal.pone.0319392
Vancouver
Le MN, Chen D, Smith KA, Tran DD, Fan ZH. Microfluidic isolation and release of live disseminated breast tumor cells in bone marrow. PLOS ONE. 2025;20(3):e0319392. doi:10.1371/journal.pone.0319392
BibTeX
@article{Le2025,
author = {Le, Minh-Chau N and Chen, Dongjiang and Smith, Kierstin A and Tran, David D and Fan, Z Hugh},
title = {Microfluidic isolation and release of live disseminated breast tumor cells in bone marrow},
journal = {PLOS ONE},
year = {2025},
volume = {20},
number = {3},
pages = {e0319392},
doi = {10.1371/journal.pone.0319392}
}
EUVIMED